spacer
 
|

Earn 1.5 CME Credits

Click below to register.


SUNDAY, JUNE 2, 2019

Hilton Chicago

720 S Michigan Ave
Chicago, IL

Room: Salon A-5

Registration and Dinner 6:00 PM – 6:30 PM
Interactive CME Symposium 6:30 PM – 8:00 PM


This activity is supported by an educational grant from Tesaro, Inc.


Not an official event of the 2019 ASCO Annual Meeting.
Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.


OVERVIEW AND GOAL
The recent introduction of poly-(ADP ribose)-polymerase (PARP) inhibitors, which exploit underlying DNA damage repair pathology, have largely shifted the ovarian cancer (OC) clinical landscape. These therapies now offer patients, who previously had little or no treatment options, a potentially life-prolonging therapy. Despite this, the need for better therapies for OC patients remain, as previous therapies have offered only minimal benefit. Further insights into the nuances of DNA damage repair and the specific deficiencies that contribute OC and EC oncogenesis have resulted in identifying new treatments, including immune-checkpoint inhibitors , as well as unique and potentially synergistic therapy combinations. Treating patients with these drug classes within the gynecological cancer landscape represents a novel development about which oncology healthcare providers struggle to remain up-to-date.

The University of Texas MD Anderson Cancer Center and its educational partner, ASiM CE LLC, will provide this live and on-demand educational initiative, which will feature animated video segments and leverage patient-focused content to facilitate learner interaction, and merge clinical decision-making with evidence-based concepts to provide memorable, relevant, and retainable learning encounters.


INTENDED AUDIENCE
This activity is intended for academic and community medical oncology healthcare providers, primarily physicians, who care for patients with ovarian and endometrial cancers. Nurse practitioners, physicians’ assistants, nurses, and other healthcare professionals involved in patient management will also find this content appropriate

LEARNING OBJECTIVES
After completing this activity, the participant should be better able to:
  • EXPLAIN deficient DNA damage repair in ovarian cancer (OC) and endometrial cancer (EC), and mechanisms by which PARP inhibitors and immune checkpoint inhibitors (ICIs), target this pathology.
  • REVIEW the efficacy, safety, and clinical utility of PARP inhibitor sequential and combination therapy in OC and EC.
  • DESCRIBE clinical practice implications of PARP inhibitors and ICIs on genetic testing, patient selection, and adverse event management.
ACCREDITATION/CREDIT DESIGNATION
MDAndersonThe University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EDUCATIONAL METHODS
Didactic Lecture, Case Study, Audience Response System, Pre-/Post-Test, Question/Answer Sessions.

EVALUATION
A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics

AGENDA
6:30 – 6:35 PM Welcome and Introduction
6:35 – 6:50 PM Deficient DNA Damage Repair in Ovarian Cancer (OC) and Endometrial Cancer (EC)
6:50 – 7:10 PM Examining the Evidence for PARP Inhibitors and Combinations in OC
7:10 – 7:30 PM Clinical Conundrums with PARP Inhibitors and Combinations in OC and EC
7:30 – 7:50 PM The Developmental Landscape in OC and EC
7:50 – 8:00 PM Q&A

This schedule is subject to change.

PARTICIPATING FACULTY
Robert L. Coleman, MD, FACOG, FACS (Course Director)
Professor and Ann Rife Cox Chair
Department of Gynecologic Oncology and Reproductive Medicine
Executive Director, Cancer Network
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ritu Salani, MD, MBA
Associate Professor
College of Medicine
Obstetrics and Gynecology
The Ohio State University
Columbus, Ohio

FEE INFORMATION
There is no fee for this educational activity.

Submit a case to review at meeting:


<img src="http://www.jhasio1.com/asim/pictures/proceed_pretestASIM.png" alt="procced to pretest" border="0" />


spacer  
  spacer
MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us
spacer  
spacer